The FDA is calling on the US Congress to work with them on a new regulatory pathway for cannabidiol (CBD). CBD is the non-psychoactive ingredient from the cannabis plant generally considered to have wellness properties.
According to the FDA, there have been some safety concerns around CBD, especially with its long-term use. The concerns around the substance relate to its potential to harm the liver, possibilities that it may be detrimental to the male reproductive system as well as the way it interacts with certain other medications.
